> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# OraSure Grows Sales 14% — But Its Adjusted Net Loss Gets Bigger
- URL: https://www.bullished.co/orasure-grows-sales-14-but-its-adjusted-net-loss-gets-bigger-85df2665/
- Published: 2026-11-09T22:26:37.000Z
- Updated: 2026-11-09T22:26:37.000Z
- Description: HIV testing and sample-management orders lifted sales, while OraSure projects $30.0 million to $32.0 million in fourth-quarter revenue.
- Author: Matteo Parrino
- Tags: Earnings, OSUR, Industry: Healthcare

OraSure Technologies, which makes rapid diagnostic tests and biological-sample collection devices, grew third-quarter sales [14% to $30.9 million](https://www.sec.gov/Archives/edgar/data/0001116463/000111646326000061/osur-20261109.htm?ref=bullished.co) from $27.1 million a year earlier, according to the earnings release accompanying its SEC filing Monday. Better production margins and a smaller operating loss did not carry through to its adjusted net loss, which widened to $10.1 million from $9.8 million.

## Better Margins, Still Losing Money

OraSure kept more of each sales dollar after covering product and service costs: its [gross margin improved](https://www.sec.gov/Archives/edgar/data/0001116463/000111646326000061/osur-pressreleasexq32026.htm?ref=bullished.co) to 45.2% from 43.5%. Management credited operating efficiencies that spread fixed costs more effectively, with the mix of products partly offsetting those gains. Adjusted gross margin reached 45.9%, versus 44.2%.

The operating loss narrowed to $13.0 million from $16.1 million; on an adjusted basis, it fell to $10.2 million from $12.7 million. Research spending dropped to $7.6 million from $10.1 million, while sales and marketing and general administrative expenses increased.

Below the operating line, other income fell to $1.2 million from $2.8 million and tax expense increased. The standard-accounting net loss narrowed to $13.1 million from $13.7 million, with the per-share loss unchanged at $0.19\. The adjusted per-share loss grew to $0.15 from $0.13.

## HIV Tests And Sample Orders Grow

Diagnostics generated [$16.8 million in sales](https://www.globenewswire.com/news-release/2026/11/09/3398945/11732/en/orasure-announces-third-quarter-2026-financial-results-strategic-execution-drives-double-digit-year-over-year-growth-and-margin-expansion.html?ref=bullished.co), up 16%, as HIV and hepatitis C testing revenue increased and BioMedomics’ Sickle SCAN contributed sales. Sample management grew 21% to $12.5 million; OraSure attributed that increase to growth among key commercial customers and when particular orders arrived. Total revenue rose 1% from the prior quarter.

The business serves healthcare providers and home users, alongside laboratories, researchers, pharmaceutical companies and consumer genetics businesses. OraSure sells tests and devices that collect and preserve samples both directly and through distributors in the United States and abroad.

During the third quarter, OraSure booked initial sales of Colli-Pee•Dx and OraQuick Ebola 2.0\. The urine-collection kit allows patients to collect first-void samples privately at home for Roche’s cobas platform and is cleared for Roche tests for chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium.

The Ebola test is authorized for whole-blood testing in living patients and oral-fluid testing from deceased people suspected of having Ebola when they died. It detects Bundibugyo, Zaire, Sudan and Taï Forest viruses. OraSure is also working with molecular-diagnostics partners on early development of a potential HPV-testing use for Colli-Pee•Dx.

## Cash Funds The Profitability Push

OraSure [used $34.7 million](https://www.globenewswire.com/news-release/2026/11/09/3398945/11732/en/orasure-announces-third-quarter-2026-financial-results-strategic-execution-drives-double-digit-year-over-year-growth-and-margin-expansion.html?ref=bullished.co) in operating cash during the first nine months of 2026, versus $40.0 million a year earlier. Cash and equivalents totaled $148.2 million on September 30, down from $199.3 million at the end of 2025\. Capital spending totaled $5.0 million, and share repurchases consumed $7.0 million during the nine-month period.

The growth effort follows the discontinuance of risk-assessment testing, which brought costs and an asset-sale gain in 2025, and workforce-reduction severance costs earlier in 2026\. Revenue for the first nine months rose just 1% to $89.5 million; adjusted net losses increased to $40.9 million from $37.2 million.

President and CEO Carrie Eglinton Manner said OraSure would invest to “improve our operating model, and [drive towards profitability](https://www.sec.gov/Archives/edgar/data/0001116463/000111646326000061/osur-pressreleasexq32026.htm?ref=bullished.co).” OraSure projects fourth-quarter revenue of $30.0 million to $32.0 million, which would put full-year revenue growth at 4.7% at the midpoint.

Management expects full-year revenue growth to accelerate in 2027 compared with 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ORASURE TECHNOLOGIES INC (OSUR)](https://www.sec.gov/Archives/edgar/data/0001116463/000111646326000061/osur-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit osur-pressreleasexq32026.htm — ORASURE TECHNOLOGIES INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001116463/000111646326000061/osur-pressreleasexq32026.htm?ref=bullished.co) — SEC EDGAR
- [OraSure Announces Third Quarter 2026 Financial Results;](https://www.globenewswire.com/news-release/2026/11/09/3398945/11732/en/orasure-announces-third-quarter-2026-financial-results-strategic-execution-drives-double-digit-year-over-year-growth-and-margin-expansion.html?ref=bullished.co) — globenewswire.com